Healthcare company Merz North America, the U.S. affiliate of Merz Pharma Group, has appointed Salisa Hauptmann as chief compliance officer, effective March 9. She will join Merz’s North American leadership team and will report directly to Bill Humphries, president and CEO of Merz North America.
As chief compliance officer, Hauptmann will be responsible for providing strategic and operational leadership to Merz on matters relating to compliance issues, including industry standards established by the Department of Health and Human Services, the Office of Inspector General, and other federal and state agencies.
Prior to joining Merz, Hauptmann served as vice president, global regulatory affairs—emerging markets Asia Pacific and Europe for GlaxoSmithKline. She brings more than 20 years of pharmaceutical, regulatory, and compliance experience to her new role as chief compliance officer.
Previous roles include time spent at Stiefel Laboratories and Novartis. She has a breadth of experience across multiple specialties, including dermatology, neurology, oncology, and respiratory disorders.
Global CCO Appointment
As a key part of this transition, Katrina Church has been appointed chief compliance officer for Merz Pharma Group, the Frankfurt-based parent company of Merz North America. Church will join Merz’s global management team as a member of the Merz Pharma board and will report directly to Merz Pharma Group CEO Philip Burchard.
Church joined Merz in 2009 as corporate counsel and chief compliance officer. She brings over 23 years of legal experience, as well as a direct experience in medical devices and dermatology to her new global appointment.